• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec to Present at ThinkEquity Conference 2019

Apr 29, 2019 8:00am EDT

OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors

Apr 24, 2019 8:00am EDT

OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer

Apr 23, 2019 8:00am EDT

OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

Apr 17, 2019 8:00am EDT

OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12

Apr 10, 2019 8:00am EDT

OncoSec to Present at H.C. Wainwright Global Life Sciences Conference

Apr 09, 2019 8:00am EDT

OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress

Apr 08, 2019 8:00am EDT

OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

Apr 02, 2019 8:00am EDT

OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO™ in Refractory Metastatic Melanoma

Apr 01, 2019 8:00am EDT

OncoSec To Host Key Opinion Leader Symposium On April 5, 2019

Mar 27, 2019 8:16am EDT
RSS
  • Prev
    • 1...
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • ...46
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    24 N. Main St
    Pennington, NJ 08534

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.